Jan 21, 2020 - Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.
Feb 04, 2020 - Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
Feb 12, 2020 -
Teva Pharmaceutical Indus (NYSE: TEVA) reported fourth-quarter earnings of 64 cents per share, which beat the analyst consensus estimate of 61 cents by 4.92%. This is a 20.75% increase over earnings of 53 cents per share from the same period last year.
Feb 12, 2020 - Teva Pharmaceutical (TEVA) matches earnings estimates but beats the same for sales. Shares rise in pre-market trading.
Feb 12, 2020 - The company's latest financial results are sparking investor optimism.
Feb 12, 2020 - The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2019 Q4 earnings call.
Feb 13, 2020 - Leaner, More Agile Teva Has Brighter Days Ahead, Stocks: TEVA,AMGN,LLY, release date:Feb 13, 2020
Feb 13, 2020 - Leaner, More Agile Teva Sees Brighter Days Ahead, Stocks: TEVA,AMGN,LLY, release date:Feb 13, 2020
Feb 19, 2020 - Stock price has bounced significantly, debt load has declined substantially, and bond yields have fallen meaningfully.More than anything, the recent earnings report has proven that the company remains
Feb 19, 2020 - Teva exceeded market expectations in the fourth quarter.Prospects continue to improve, driven by strong generic pipeline and two drugs.Fair value on Teva stock modelled.